Astellas, Seattle Genetics ADC could provide new option for checkpoint non-responders in bladder cancer

Data presented at ASCO on Monday for Astellas and Seattle Genetics' enfortumab vedotin showed that metastatic bladder cancer patients who don't respond or relapse after PD-1/PD-L1 therapy could soon have a new treatment option.

In the first cohort of 125 patients in the pivotal Phase II EV-201 trial of

Read the full 484 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE